by Ryan Michalek | Jul 22, 2022 | Press Releases
Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 – (GLOBE NEWSWIRE) – Heat Biologics,...
by Ryan Michalek | Jul 22, 2022 | Press Releases
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government New contract marks the first international sale of ANTHIM® and follows recent acquisition of Elusys by...
